Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109379 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
A Phase 1 study, sponsored by Taris Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03109379 is a Phase 1 study that has completed, run by Taris Biomedical. The registered enrollment target is 43 participants.
The verdict
NCT03109379, a Phase 1 study, has completed, sponsored by Taris Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
Interventions
- DRUG Trospium-Releasing Intravesical System (TAR-302-5018)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03109379
The ClinicalTrials.gov registry entry for NCT03109379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taris Biomedical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trospium-Releasing Intravesical System (TAR-302-5018) is the first listed.
NCT03109379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03109379 about?
NCT03109379 is a clinical study titled "Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder". The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
What is the current status of trial NCT03109379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2017-04-04. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03109379?
The interventions under investigation include: Trospium-Releasing Intravesical System (TAR-302-5018) (DRUG).
Who is sponsoring clinical trial NCT03109379?
This trial is sponsored by Taris Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.